Trial · NCT07245446
A Study of Ivonescimab in First-Line ES-SCLC
NCT07245446, Phase 2, Recruiting, Akeso
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of Ivonescimab in First-Line ES-SCLC. Trials, record NCT07245446. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07245446
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of Ivonescimab in First-Line ES-SCLC
- NCT number
- NCT07245446
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 180 participants, estimated
- Lead sponsor
- Akeso
- Conditions
- Extensive-stage Small Cell Lung Cancer (ES-SCLC)
- Interventions
- Ivonescimab, Cadonilimab, AK117, Etoposide, Carboplatin (AUC 5)
- First posted
- 2025-11-24
- Last updated
- 2025-11-24
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective Response Rate (ORR) | Up to approximately 2 years. | The proportion of participants achieving a Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR), as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. |
| Primary | Incidence of Adverse Events (AEs) | From first dose up to 90 days after last dose. | The number and percentage of participants experiencing any Adverse Event (AE). An AE is defined as any untoward medical occurrence in a participant administered a study drug, which may not have a causal relationship with the treatment. Severity will be graded per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0. |
| Secondary | Disease Control Rate (DCR) | Up to approximately 2 years. | The proportion of participants achieving a BOR of CR, PR, or Stable Disease (SD), as assessed by the investigator per RECIST v1.1. |
| Secondary | Duration of Response (DoR) | Up to approximately 2 years. | For responders (participants achieving CR or PR), DoR is defined as the time from the first documented evidence of CR or PR until the first documented disease progression or death from any cause, whichever occurs first, per RECIST v1.1. |
| Secondary | Time to Response (TTR) | Up to approximately 2 years. | For responders (participants achieving CR or PR), TTR is defined as the time from the start of study treatment to the first documented objective response (CR or PR), per RECIST v1.1. |
| Secondary | Progression-Free Survival (PFS) | Up to approximately 2 years. | PFS is defined as the time from the start of study treatment to the first documented disease progression per RECIST v1.1 or death from any cause, whichever occurs first. |
| Secondary | Overall Survival (OS) | Up to approximately 5 years. | OS is defined as the time from the start of study treatment to death from any cause. |
| Secondary | Serum concentrations of Ivonescimab, Cadonilimab, and AK117 | Up to approximately 2 years. | Serum concentrations of Ivonescimab, Cadonilimab, and AK117 will be measured to characterize the pharmacokinetic (PK) profiles. |
| Secondary | Incidence of Anti-drug Antibodies (ADA) | Up to approximately 2 years. | The immunogenicity will be assessed by the incidence of participants who develop detectable anti-drug antibodies (ADA) against Ivonescimab, Cadonilimab, and/or AK117. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07245446
GET https://conductscience.org/api/trials/v1/NCT07245446/registered